VIDEO: Treatment intensification in metastatic prostate cancer ‘underutilized’
CHICAGO — In this video, Stephen J. Freedland, MD, discusses how intensification of androgen deprivation therapy using novel hormonal therapies remains underutilized in patients with de novo metastatic castration-sensitive prostate cancer.
When presented at the ASCO Annual Meeting, Freedland, urologist at Cedars-Sinai Medical Center and Durham VA Medical Center, discussed how treatment intensification has proven to show better outcomes and higher survival rates despite being underutilized.
“We know that treatment intensification improves outcomes and improves survival. We know it’s underutilized. We want to assess that because we were able to do a chart review on 380 patients to understand high volume vs. low volume, and whether it’s different in terms of the degree of treatment intensification,” Freedland said.
Of the 380 patients with de novo metastatic castration-sensitive prostate cancer reviewed, 57% had high-volume and 43% had low-volume disease in the retrospective study using the Veterans Affairs Informatics and Computing Infrastructure.
“Unfortunately, intensification rates were underutilized in both groups. It was more often used in the high-volume patients, but overall use was relatively low across the board,” Freedland said.
“There was some other data that says care within the VA tends to be better and higher than care outside of the VA, but even in this setting we’re still seeing underutilization. Identifying what those barriers are and how to overcome them is certainly the future in where we need to be going with this,” Freedland continued.
Reference:
- Freedland S, et al. Abstract e17081. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Healio interviews
Read more about